Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced the expiration of the 30-day “go-shop” period pursuant to the terms of the previously announced definitive merger agreement, entered into on October 2, 2011, between PPD and affiliates of The Carlyle Group and affiliates of Hellman & Friedman LLC.
During the “go-shop” period, which ended at 11:59 p.m., Eastern Time, on November 1, 2011, the company's representatives solicited superior proposals from third parties. Despite these solicitation efforts, PPD did not receive any alternative acquisition proposals during the “go-shop” period.
On October 3, 2011, PPD announced that it had entered into a definitive merger agreement under which PPD will be acquired by affiliates of The Carlyle Group and affiliates of Hellman & Friedman LLC in an all-cash transaction. Pursuant to terms of the agreement, PPD shareholders will receive $33.25 in cash for each share of common stock.
PPD has also been granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the proposed merger. The transaction remains subject to antitrust clearance in certain foreign jurisdictions and approval by PPD’s shareholders, as well as other customary closing conditions. PPD has scheduled a special meeting of its shareholders for November 29, 2011, to consider approval of the merger agreement and expects the merger to close in the fourth quarter of 2011. PPD’s board of directors continues to recommend that PPD’s shareholders vote to approve the merger agreement at the special meeting of shareholders.
PPD is a leading global
contract research organization
providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the merger, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: risks that the merger might not close; risks that PPD might lose customers and/or employees as a result of announcement of the merger; overall global economic conditions; economic conditions in the pharmaceutical, biotechnology and government-sponsored research sectors; research and development spending in the pharmaceutical, biotechnology and government-sponsored research sectors; outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in pharmaceutical and biotechnology industries; competition in the outsourcing industry; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; fluctuations in currency exchange rates; the ability to attract, integrate and retain key personnel; and risks associated with and dependence on strategic relationships. These and other PPD risk factors are set forth in more detail from time to time in our SEC filings, copies of which are available free of charge upon request from PPD’s investor relations department. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
Additional Information and Where to Find It
In connection with the proposed merger, PPD filed a definitive proxy statement with the SEC on October 28, 2011, which it is in the process of mailing, along with a form of proxy, to shareholders of record of the company as of October 24, 2011. PPD’S SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. PPD’s shareholders may obtain, without charge, a copy of these documents from the SEC’s website at
. PPD’s shareholders will also be able to obtain, without charge, a copy of the definitive proxy statement and other relevant documents by going to the Investors section of PPD’s corporate website,
PPD and its directors and officers may be deemed to be participants in the solicitation of proxies from PPD’s stockholders with respect to the proposed merger. Information about PPD’s directors and executive officers and their ownership of PPD’s common stock is set forth in the definitive proxy statement for the company’s November 29, 2011, special meeting of shareholders, which was filed with the SEC on October 28, 2011. Shareholders may obtain additional information regarding the interests of the company and its directors and executive officers in the proposed merger, which may be different than those of the company’s shareholders generally, by reading the definitive proxy statement filed with the SEC on October 28, 2011, and other relevant documents regarding the proposed merger, when filed with the SEC.